Tirzepatide vs Cagrilintide
Tirzepatide has large Phase III/approved-product evidence; cagrilintide monotherapy evidence is Phase II. Compare evidence maturity and mechanism rather than declare a winner.
| Attribute | Tirzepatide | Cagrilintide |
|---|---|---|
| Human evidence | Large Phase III obesity evidence shows substantial weight loss. SURMOUNT-OSA additionally demonstrated large reductions in sleep-apnea severity in adults with obesity and moderate-to-severe OSA. | Cagrilintide has randomized Phase II evidence and a Phase IIIa monotherapy arm within REDEFINE 1; the dedicated RENEW Phase 3 monotherapy programme is underway. |
| Research focus | Type 2 diabetes, obesity, weight management | Obesity, appetite and weight-management research |
| Regulatory status | Tirzepatide is authorised in licensed products such as Mounjaro for type 2 diabetes and adult weight management in the EU; authorization is product- and jurisdiction-specific. | FDA states cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in U.S. compounding under federal law. |
| Route / formulation | Unverified research-market material or non-authorised pens are not equivalent to licensed tirzepatide medicines merely because the active-ingredient name matches. | Trial evidence does not establish quality or equivalence of research-market material. |
Why these are compared
These compounds appear in the weight-management evidence evidence landscape, but they are not interchangeable. Tirzepatide is gip/glp-1 receptor agonist peptide studied in type 2 diabetes, obesity, weight management; Cagrilintide is long-acting amylin analogue peptide studied in obesity, appetite and weight-management research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Tirzepatide: Strong Phase III / approved-product evidence across multiple indication-specific outcomes.
Cagrilintide: Phase 3 monotherapy evidence and development; investigational / not FDA-approved.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No simple monotherapy head-to-head basis. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.